Recombinant Antibodies For Immunotherapy - Little Melvyn (Curatore) | Libro Cambridge University Press 07/2009 -

home libri books ebook dvd e film top ten sconti 0 Carrello

Torna Indietro

little melvyn (curatore) - recombinant antibodies for immunotherapy

Recombinant Antibodies for Immunotherapy

Disponibilità: Normalmente disponibile in 15 giorni
A causa di problematiche nell'approvvigionamento legate alla Brexit sono possibili ritardi nelle consegne.

105,98 €
100,68 €

Questo prodotto usufruisce delle SPEDIZIONI GRATIS
selezionando l'opzione Corriere Veloce in fase di ordine.

Pagabile anche con 18App Bonus Cultura e Carta del Docente

Facebook Twitter Aggiungi commento

Spese Gratis


Lingua: Inglese
Pubblicazione: 07/2009

Note Editore

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.


Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter; Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naïve V gene sources G. Beste and D. Lowe; 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss; Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge; 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits; 6. Transgenic chimeric antibodies A. Murphy; Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha; 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters; 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker; Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster; 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain; 12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana; Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King; 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos; 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones; Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little; 17. Single domain antibodies S. Muyldermans; 18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp; Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun; Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys; 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie; Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo; 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe; 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig; Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.


A comprehensive overview of the field of monoclonal antibodies (mAbs) through twenty-five articles by experienced authors, covering examples of recombinant antibodies, used in the clinic or in development. Appealing to scientists, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.


Melvyn Little's research group at the German Cancer Research Center (DKFZ) in Heidelberg was one of the first to develop methods for making and screening antibody libraries. After co-founding Affitech (Oslo, Norway) in 1997, he left the DKFZ in 2000 to found Affimed Therapeutics, a biotechnology company in Heidelberg specializing in the isolation and engineering of human antibodies to treat various diseases, especially cancer. He has been an extracurricular Professor of Biochemistry at the University of Heidelberg since 1986.

i libri che interessano a chi ha i tuoi gusti

Altre Informazioni



Condizione: Nuovo
Dimensioni: 260 x 28 x 181 mm Ø 1210 gr
Formato: Copertina rigida
Illustration Notes:50 b/w illus. 11 colour illus. 32 tables
Pagine Arabe: 434

Utilizziamo i cookie di profilazione, anche di terze parti, per migliorare la navigazione, per fornire servizi e proporti pubblicità in linea con le tue preferenze. Se vuoi saperne di più o negare il consenso a tutti o ad alcuni cookie clicca qui. Chiudendo questo banner o proseguendo nella navigazione acconsenti all’uso dei cookie.